Industry experts committed to cures.
Jeffrey Chulay, M.D., DTM&H
Executive Director, Clinical Strategy
Dr. Chulay brings broad medical and regulatory expertise to AGTC. Since joining the company in 2007, he has achieved Investigational New Drug submissions for programs in Alpha-1 Antitrypsin Deficiency, Leber Congenital Amaurosis, X-linked Retinoschisis and Achromatopsia, and published clinical trial results for the first two of these programs.
Prior to joining AGTC, Dr. Chulay served as Senior Vice President and Chief Medical Officer at AlphaVax, where he led successful clinical trial programs of recombinant viral vector vaccines for cytomegalovirus and influenza. Dr. Chulay has also worked at GlaxoSmithKline as the Principal Clinical Program Head in HIV and Opportunistic Infections, responsible for bringing two anti-infective drugs to market; Walter Reed Army Medical Institute of Research (WRAIR) as Chief of the Department of Immunology; and U.S. Army Research Institute of Infectious Disease as Chief of the Virology Division. Dr. Chulay earned a medical degree from Northwestern University Medical School and a degree in tropical medicine and hygiene from the London School of Hygiene and Tropical Medicine. He served his residency at Cleveland Metropolitan General Hospital and was a fellow in Infectious Disease at WRAIR. He has been a member of the Institute of Medicine Committee on Prevention and Control of Malariaand an advisor to the Institute of Medicine Committee on the Independent Review and Assessment of the Activities of the NIH Recombinant DNA Advisory Committee (RAC). He has published more than 100 papers in peer-reviewed journals and is a reviewer for several leading medical journals.
- Our Team
- Board of Directors
- Scientific Advisors
- Careers and Internships